U.S. Markets close in 5 hrs 59 mins

CLASS ACTION UPDATE for WSR, NTNX, BA and XENT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Whitestone REIT (WSR)
Class Period:
May 9, 2018 - February 27, 2019
Lead Plaintiff Deadline: June 17, 2019
Join the action: https://www.zlk.com/pslra-1/whitestone-reit-loss-form?wire=3

Allegations: Whitestone REIT made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the Company lacked effective internal control over financial reporting; (2) Whitestone was incorrectly recognizing assets and liabilities associated with its contribution to Pillarstone Capital REIT Operating Partnership LP; (3) the Company’s financial statements for the fiscal year 2018 were overstating revenues; (4) the Company’s financial statements for the fiscal year 2018 could no longer be relied upon; and (5) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.

To learn more about the Whitestone REIT class action contact jlevi@levikorsinsky.com.

Nutanix, Inc. (NTNX)
Class Period:
Class A shares purchased between March 2, 2018 and February 28, 2019
Lead Plaintiff Deadline: May 28, 2019
Join the action: https://www.zlk.com/pslra-1/nutanix-inc-loss-form?wire=3

The complaint concerns whether the Company and its executives violated federal securities laws by making false and/or misleading statements about its investments in growth and its maintenance of high profit margins.  On February 28, 2019, Nutanix announced its second quarter fiscal 2019 results and reported third quarter guidance that was below analysts' expectations. Management acknowledged that "inadequate marketing spend for pipeline generation and slower than expected sales hiring" were the reasons for the weak guidance. On this news, Nutanix's share price fell from $50.09 per share on February 28, 2019 to a closing price of $33.70 on March 1, 2019.

To learn more about the Nutanix, Inc. class action contact jlevi@levikorsinsky.com.

The Boeing Company (BA)
Class Period:
January 8, 2019 - March 21, 2019
Lead Plaintiff Deadline: June 10, 2019
Join the action: https://www.zlk.com/pslra-1/the-boeing-company-loss-form-2?wire=3

Allegations: During the class period, The Boeing Company made materially false and/or misleading statements and/or failed to disclose that: (1) Boeing’s 737 MAX airplanes were not as safe as previous models, therefore Boeing included undisclosed “hacks” created by engineering compromises and the lack of safety features which Boeing sold as “optional” add-ons which were designed to help address these safety concerns; (2) most airlines did not purchase these safety “options”; (3) the Federal Aviation Administration granted Boeing its own oversight and certification of Boeing’s new flight control system, or Maneuvering Characteristics Augmentation Systems, which was a clear conflict of interest as Boeing was rushing the 737 MAX airplanes to market; and (4) as a result of the foregoing, Boeing’s public statement were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the The Boeing Company class action contact jlevi@levikorsinsky.com.

Intersect ENT, Inc. (XENT)
Class Period:
August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline: July 15, 2019
Join the action: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?wire=3 

Allegations: Intersect ENT, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; (2) Intersect’s sales force would focus on ensuring reimbursement; (3) Intersect’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Intersect ENT, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com